SNGX
Soligenix, Inc. Common Stock
Latest price
As of Oct 30, 2026, 7:17 PM EDT · Market data by Massive
Market cap
$7.7M
Volume
69.7K
Previous close
$0.3693
Day range
$0.3361 – $0.3776
Listed
Apr 5, 1994
Coverage
5 articles
Price performance
Recent trading
Newsroom
Latest SNGX coverage
Soligenix, Inc. CEO is Featured in an Interview with SmallCaps Daily
[ad_1] NEW YORK, NY – (NewMediaWire) – June 29, 2023 – Soligenix, Inc. (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, is excited to announce its CEO, President, and Chairman, Christopher J. Schaber, recently conducted an i
Soligenix On Track to Deliver Important Front-Line Treatment to US Market in 2024
[ad_1] Company Seeks Approval for Reverse Stock Split to Maintain Nasdaq Listing NEW YORK, NY – (NewMediaWire) – January 12, 2023 – PCG Digital — Late-stage biopharmaceutical company, Soligenix, Inc. (Nasdaq: SNGX) is on track to deliver a safe and effective front-line treatment to a community of patients living with a rare, chronic
Soligenix, Inc. to Showcase 2022 Milestones in Business Update Fireside Chat with PCG Advisory
[ad_1] Interview to be webcast on November 29, 2022 at 11:00 am ET New York, NY – (NewMediaWire) – November 16, 2022 – Soligenix, Inc., (Nasdaq: SNGX) (the “Company” or “Soligenix”), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, will joi
Highlights and Insights into Soligenix
[ad_1] Dr. Chris Schaber Discusses Soligenix HyBryte™ and Thermostabilized Vaccines New York, NY – (NewMediaWire) – October 13, 2021 – PCG Digital — In a recent interview with Kristen Kluska, a biotechnology analyst at Cantor, Dr. Chris Schaber, President and CEO of Soligenix (SNGX), spoke about the latest developments with their synt
HyBryte(TM): Addressing an Unmet Need for Rare Lymphoma
[ad_1] Soligenix Demonstrates Clinical Success in First-in-Class Treatment for Cutaneous T-Cell Lymphoma New York, NY – (NewMediaWire) – July 22, 2021 – PCG Digital — Cutaneous T-cell lymphoma (CTCL) is a rare form of non-Hodgkin’s lymphoma that currently affects between 16,000 – 20,000 Americans, with approximately 1,000 new